We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05007496
Recruitment Status : Completed
First Posted : August 16, 2021
Last Update Posted : August 20, 2021
Sponsor:
Collaborators:
PT AIVITA Biomedika Indonesia
Kariadi Hospital
Central Army Hospital RSPAD Gatot Soebroto
Information provided by (Responsible Party):
Aivita Biomedical, Inc.

Brief Summary:
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection. The product is a subject-specific personal vaccine that consists of autologous dendritic cells and lymphocytes (DCL) previously incubated with a quantity of SARS-CoV-2 spike protein (S-protein) which was shown to be safe in a phase 1 study also conducted in Indonesia. In this phase 2 study, efficacy is assessed via enhanced S-protein-specific T-cell response by comparing results before and after vaccination. Safety is confirmed via laboratory values, observation and regular patient reporting.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: AV-COVID-19 Phase 2

Detailed Description:
In this phase 2 study, a single dose of AV-COVID-19 DCL vaccine is injected subcutaneously in the forearm (left or right) at week 0 (day-0), to facilitate inspection and avoid confusion of local post-injection reactions or shoulder pain. Follow-up visits to assess safety are performed at 1, 2, and 4 weeks after vaccination, with laboratory safety tests performed at weeks 1 and 4, and only at week 2 if any clinically significant changes at screening up to week 1. At each visit, the injection site is assessed, and the subject is asked about symptoms, and at weeks 0 (baseline before injection), 2 and 4, blood is drawn for immunogenicity testing. Reaction data at the injection site and safety profile are obtained by telephone to subjects on days 1, 2, and 3 after vaccine injection. Subjects are asked specifically about local injection site reactions and systemic flu-like symptoms (fever, chills, muscle aches, joint pain) for 7 days after injection. Adverse events (AE) are collected for 28 days after injection. Evaluation of laboratory tests for clinical safety parameters are carried out at screening as well as immediately before vaccination and on day 7 and day 28 post-vaccination. Serious adverse events (SAE), recent medical conditions, and other events requiring medical intervention are recorded for 2 months after vaccination. Vaccine enabling kits are made by PT AIVITA Biomedika Indonesia. All vaccines are made in Indonesia on site at participating hospitals and clinical sites.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 145 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19
Actual Study Start Date : April 14, 2021
Actual Primary Completion Date : May 31, 2021
Actual Study Completion Date : May 31, 2021


Arm Intervention/treatment
Experimental: AV-COVID-19 (0.1 mcg S-protein)
DCL previously incubated with 0.1 mcg spike protein
Biological: AV-COVID-19
DCL previously loaded with varying quantity of S-protein

Experimental: AV-COVID-19 (0.33 mcg S-protein)
DCL previously incubated with 0.33 mcg spike protein
Biological: AV-COVID-19
DCL previously loaded with varying quantity of S-protein

Experimental: AV-COVID-19 (1.0 mcg S-protein)
DCL previously incubated with 1.0 mcg spike protein
Biological: AV-COVID-19
DCL previously loaded with varying quantity of S-protein




Primary Outcome Measures :
  1. Efficacy based on T-cell-induced immune response [ Time Frame: 4 weeks ]
    ELISPOT assay at baseline, week 2 and week 4 post-vaccination


Secondary Outcome Measures :
  1. Adverse event frequency and incidence [ Time Frame: 4 weeks ]
    Confirm safety of AV-COVID-19 via laboratory values and adverse event reporting from baseline to 28-days post-vaccination

  2. Optimal formulation [ Time Frame: 4 weeks ]
    Choose the optimal formulation (0.1, 0.33, 1.0 mcg S-protein)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Understands and agrees to comply with research procedures and provides written informed consent
  • Physical and mental health meet criteria to participate, which includes factors associated with increased risk of exposure to SARS-CoV-2, such as age > 65, mild to moderate obesity (BMI 30-40), hypertension controlled with medication, drug controlled hyperlipidemia, diabetes controlled with medication, mild chronic lung disease
  • Vein access permits for blood collection
  • For people with reproductive ability, adequate contraception and negative pregnancy test for women

Exclusion Criteria:

  • Have active symptoms of COVID-19 infection
  • Diagnosed with COVID-19 with a positive PCR test in the past 3 months
  • Positive SARS-CoV-2 rapid antibody IgG test
  • Positive pregnancy test
  • Known to have immunodeficiency disease
  • Are taking immunosuppresive drugs and/or corticosteroids in the long term
  • Have a condition requiring oxygen supplementation
  • Previously diagnosed with invasive cancer and receiving anti-cancer therapy in addition to hormonal therapy for breast or prostate cancer
  • History of thromboembolism or genetic predisposition to thromboembolism, or being on anti-thromboembolic therapy other than low-dose aspirin
  • Physical or mental disability that prevents you from carrying out normal daily activities
  • In the Investigator's judgement, have illnesses or medical conditions that could preclude participation
  • Excessive obesity: BMI > 40
  • Uncontrolled hypertension: systolic > 180, diastolic > 100
  • Not willing to sign written consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05007496


Locations
Layout table for location information
Indonesia
RSPAD Gatot Soebroto
Jakarta, Indonesia
Sponsors and Collaborators
Aivita Biomedical, Inc.
PT AIVITA Biomedika Indonesia
Kariadi Hospital
Central Army Hospital RSPAD Gatot Soebroto
Investigators
Layout table for investigator information
Principal Investigator: Dr Jonny, SpPD-KGH, MKes, MM Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Layout table for additonal information
Responsible Party: Aivita Biomedical, Inc.
ClinicalTrials.gov Identifier: NCT05007496    
Other Study ID Numbers: CL-COV-P02-ID
First Posted: August 16, 2021    Key Record Dates
Last Update Posted: August 20, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aivita Biomedical, Inc.:
Prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases